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Objectives: Ivacaftor, a CFTR potentiator, is indicated in patients with CF 6 years
and older carrying a G551D mutation. It has been available in France since April
2012. Our aim was to review the ﬁrst data with Ivacaftor therapy in French patients
in clinical practice.
Methods: An independent retrospective survey was sent by e-mail to physicians
from French CF centres to identify patients treated with Ivacaftor. Collected
information included birth date, gender, date of ﬁrst treatment with Ivacaftor, FEV1
and weight at treatment initiation, after one, 3 and 6 months of treatment, adverse
events and any treatment interruption.
Results: Survey included 48 patients from 23 CF centres (27 males, 21 females),
with a mean age of 21.3 yo (6.1 to 51.8) over the April to November 2012 period.
Fourteen patients were children aged 6−12 yo. Baseline mean FEV1 (±SD) was 71.3
(±25.9) % pred. There was an increase from baseline of 8.5 (±8.7), 9.4 (±8.0) and
11.0 (±8.0) percentage points of predicted FEV1, respectively at Months 1 (n = 41),
3 (n = 35) and 6 (n = 20). Weight increased from baseline of 1.0 (±1.4), 2.3 (±2.1)
and 3.2 (±2.7) kg, respectively at Months 1, 3 and 6. Adverse events considered
as drug related included headache (n = 4), nausea (n = 2), abdominal pain (n = 1),
asthenia (n = 1), dizziness (n = 1), skin rash (n = 1), and breast hypertrophy (n = 1).
Two patients interrupted Ivacaftor from D7 to D35, one for rash, one for digestive
symptoms; events did not re-occur when Ivacaftor treatment was resumed.
Conclusion: Preliminary results with Ivacaftor in French CF patients in real world
setting were similar to clinical study data, in efﬁcacy (increase in FEV1 and weight)
and safety.
58 Pulmonary exacerbations in CF patients with the G551D-CFTR
mutation treated with ivacaftor
P. Flume1, C. Wainwright2, E. Tullis3, S. Rodriguez4, J. Davies5, J. Wagener4. 1Medical University
of South Carolina, Charleston, United States; 2University of Queensland, Brisbane, Australia;
3University of Toronto, Toronto, Canada; 4Vertex Pharmaceuticals Incorporated, Cambridge, United
States; 5Imperial College, London, United Kingdom
In Phase 3, 48-week studies of CF patients (pts) with the G551D mutation, ivacaftor provided beneﬁts,
including improved lung function, sweat chloride and fewer pulmonary exacerbations (PEs). We
analyzed data from Studies 102/103 to better understand the clinical diagnosis and treatment of PEs.
In Studies 102 (12 yrs, N = 161) and 103 (6−11 yrs, N = 52) a change in antibiotic therapy for any
of 12 protocol-deﬁned signs or symptoms was called a sinopulmonary event (SPE). SPEs with 4
signs or symptoms were deﬁned as a PE.
Over 48 weeks, there were 146 PEs in 72 pts (12 yrs) and 12 PEs in 11 pts (6−11 yrs). PEs and
SPEs are summarized in the Tables.
Pts treated with ivacaftor had fewer PEs and SPEs than controls. Although young pts (6−11 yrs)
experienced fewer PEs overall, the percentage of young pts having SPEs was comparable to the
older pts. In older pts (12 yrs), the 4 most frequently reported signs or symptoms were consistent
across the ivacaftor and placebo groups. Pts treated with ivacaftor in Study 102 had fewer reported
protocol-deﬁned signs or symptoms than controls.
Table 1. SPEs and PEs over 48 weeks
Number of patients (number of total events)
Study 102 (12 yrs) Study 103 (6−11 yrs)
Placebo (N= 78) Ivacaftor (N = 83) Placebo (N= 26) Ivacaftor (N = 26)
SPE 67 (177) 49 (115) 22 (56) 20 (50)
PE 44 (99) 28 (47) 4 (4) 7 (8)
Table 2. Incidence of protocol-deﬁned signs or symptoms in Study 102
Sign/symptom Number of times reported (% of total events)
Placebo (N= 623) Ivacaftor (N = 371)
Increased cough 145 (23.3) 99 (26.7)
Change in sputum 110 (17.7) 73 (19.7)
Malaise, fatigue, lethargy 76 (12.2) 45 (12.1)
Dyspnea 64 (10.3) 33 (8.9)
All others combined* 228 (36.6) 121 (32.6)
All others included: change in sinus discharge, change in physical examination of the chest, decrease in pulmonary
function by 10%, sinus pain or tenderness, temperature >38ºC, new or increased hemoptysis, anorexia or weight loss,
and radiographic changes indicative of pulmonary infection.
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Objectives: By improving CFTR function, potentiators (eg Ivacaftor) may correct
abnormal epithelial salt transport in certain mutation classes. We systematically
reviewed randomized controlled trials (RCTs) of potentiators in CF.
Methods: We included parallel design RCTs, published or not, evaluating poten-
tiators in children or adults with CF. Primary outcomes were FEV1, survival, and
quality of life (QoL). Secondary outcomes included weight and sweat chloride.
Published RCTs were assessed for risk of bias using Cochrane methodology. Where
appropriate, trial results were synthesized.
We included six placebo-controlled trials. Three RCTs evaluated Ivacaftor in
231 patients with G551D; two evaluated Ivacaftor added to a corrector (VX809) in
171 patients with DF508; one evaluated Ivacaftor without corrector in 140 patients
with DF508. No trial included children less than six years of age. Of the three
RCTs that have been published, two were rated as high risk of outcome reporting
bias. All three were rated as low or unclear risk of other types of bias.
Synthesis of results of two RCTs, in patients with G551D, was possible (pooled data
showing mean change from baseline [95%CI]): QoL measured with CFQR (7.85
[4.90, 10.8]); % predicted FEV1 (10.4 [8.6, 12.8]); sweat chloride (−49.8mmol/l
[−54.7, −44.9]); weight (2.75 kg (1.75, 3.74]). There was no signiﬁcant beneﬁt in
patients with DF508. Ivacaftor was well tolerated.
Conclusions: Ivacaftor has a profound impact on clinical outcomes at 48 weeks
in patients with G551D. There is no evidence to support its use in patients with
DF508. RCTs in children less than six years of age are needed.
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We recently published the ﬁrst description of correction of a CF causing mutation
(DF508) in a tracheal epithelial cell line by homology directed repair (HDR) using
zinc ﬁnger nucleases (ZFNs) and a donor plasmid (Lee et al., 2012).
At present the approach is limited to correcting one mutation. To address this, we are
using our existing cftr-speciﬁc ZFNs to target a cftr mini-gene to intron 9 with the
aim to correct CF mutations throughout exons 10−24 (~80% of all CF mutations)
with a single ZFN pair/donor plasmid. As proof-of-principle that our ZFNs can
target exogenous sequences to intron 9 we ﬁrst sought to precisely incorporate a 7
bp Tag sequence into the cftr gene at the ZFN target site by HDR using a 1.5 kb
donor plasmid. Analysis of cells treated with our ZFNs and donor by nested PCR
revealed that the Tag can be successfully introduced into the cftr gene at the correct
location.
To effect gene repair, the mini-gene repair construct requires a promoterless cftr
partial cDNA (exons 10−24) with appropriate splice acceptor and poly A sites.
Incorporation of the mini-gene would result in full length corrected CFTR mRNA
production that is under the control of the endogenous promoter, a major limitation
experienced when delivering exogenous cDNA. Li et al., 2011, previously replaced
exons 2−8 of the F9 gene restoring haemostasis in haemophilic mice using this
strategy. Successful gene correction using a mini-gene would result in normal
spatiotemporal expression of the corrected CFTR gene, that is permanent for the
lifetime of the cell and is not subject to gene silencing. It could be of use as an
alternative strategy to cDNA addition for gene therapy.
